Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors

NCT02359565 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02359565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02359565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 3, 2015
Completion date
January 16, 2027
Enrollment
71 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

constitutional mismatch repair deficiency syndrome, lynch syndrome, malignant glioma, recurrent brain neoplasm, recurrent childhood ependymoma, recurrent diffuse intrinsic pontine glioma, recurrent medulloblastoma, refractory brain neoplasm, refractory diffuse intrinsic pontine glioma, refractory ependymoma, refractory medulloblastoma